A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Glomerulonephritis; Membranous glomerulonephritis
- Focus Registrational; Therapeutic Use
- Acronyms VALIANT
- Sponsors Apellis Pharmaceuticals
- 14 Jul 2024 This trial has been Completed in Belgium, According to European Clinical Trials Database record.
- 24 May 2024 According to an Apellis Pharmaceuticals, company is looking forward to sharing the topline results later this year.
- 07 Mar 2024 Planned End Date changed from 1 Nov 2024 to 1 Dec 2024.